Clinical Trial Update: MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating MK-0646 in combination with etoposide and cisplatin for extensive-stage small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Etoposide (Etoposide)
• MK-0646 (dalotuzumab)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED